Rothe B, Guldner J, Hohlfeldt E, Lauer C J, Pollmächer T, Holsboer F, Steiger A
Max Planck Institute of Psychiatry Clinical Institute, Department of Psychiatry, Munich, Germany.
Neuropsychopharmacology. 1994 Oct;11(2):101-6. doi: 10.1038/npp.1994.39.
Two dosages (5 mg and 25 mg) of the selective 5HT3 receptor antagonist tropisetron (ICS 205-930) were administered to healthy male controls, and the effects on the sleep EEG and nocturnal secretory activity of growth hormone (GH) and cortisol were evaluated. The lower dosage was administered to four subjects and the higher dosage to eight on 5 consecutive days, preceded and followed by 2 days of placebo treatment. After 25 mg of tropisetron, there was a slight increase in REM sleep in the first part of the sleep period, and stage 2 was decreased during the total night. In addition, plasma cortisol levels increased earlier than under placebo, and plasma GH levels were reduced in the second part of the night. Thus, only discrete effects of tropisetron upon sleep-endocrine activity were noted, making it unlikely that serotoninergic neurotransmission exerts its well-documented effects upon sleep through 5HT3 receptors.
将选择性5-羟色胺3（5HT3）受体拮抗剂托烷司琼（ICS 205-930）的两种剂量（5毫克和25毫克）给予健康男性对照组，并评估其对睡眠脑电图以及生长激素（GH）和皮质醇夜间分泌活动的影响。较低剂量给予4名受试者，较高剂量给予8名受试者，连续5天给药，给药前后各有2天的安慰剂治疗期。给予25毫克托烷司琼后，睡眠期第一部分的快速眼动（REM）睡眠略有增加，整夜第二阶段睡眠减少。此外，血浆皮质醇水平比服用安慰剂时更早升高，夜间第二部分血浆GH水平降低。因此，仅观察到托烷司琼对睡眠-内分泌活动有离散效应，这使得血清素能神经传递不太可能通过5HT3受体对睡眠产生其已被充分证明的影响。
